Objective: To investigate the relationship between the metabolic syndrome and its related factors among non-diabetic pre-and post-menopausal women in North Taiwan. Design: A cross-sectional study in a medical center in North Taiwan. Subjects: Five hundred and ninety-four, non-diabetic middle-aged women (age range ¼ 40-64 years, mean ¼ 48.975.4 years) were recruited. Measurements: The fasting plasma glucose, insulin, lipids levels and anthropometric indices were measured. The homeostasis model assessment was applied to estimate the degree of insulin resistance (HOMA-IR). Metabolic syndrome was defined by using the National Cholesterol Education Panel (NCEP) criteria and modified NCEP criteria (waist circumference 480 cm). Results: The prevalence of metabolic syndrome was 6.2% using NCEP criteria, and 8.9% using modified NCEP criteria. Postmenopausal women had a higher prevalence of metabolic syndrome and its individual components compared to premenopausal women except hyperglycemia and low HDL-C. In multiple logistic regression analysis with adjustment for age and menopausal status, both BMI and HOMA-IR were independently associated with the metabolic syndrome. Conclusion: The prevalence of metabolic syndrome was higher in post-menopausal than pre-menopausal women. Both obesity and insulin resistance may play an important role in the development of metabolic syndrome among the middle-aged women in North Taiwan.
Introduction
The metabolic syndrome, a constellation of impaired glucose metabolism, dyslipidemia, hypertension, and central obesity, is associated with subsequent development of type 2 diabetes mellitus and cardiovascular diseases (CVD). 1 CVD and all-cause mortalities also increase with metabolic syndrome. 2 In Europe and the United States, the prevalence of metabolic syndrome is approximately 20% in adults. 3, 4 In
Asians, the prevalence of metabolic syndrome is around 10-20%, [5] [6] [7] depending on regions and criteria used to define metabolic syndrome. Therefore, the metabolic syndrome has become a significant health problem worldwide and requires urgent attention. However recently, a joint statement from the American Diabetes Association and European Association for the Study of Diabetes 8 indicates that classifying someone as having the metabolic syndrome can arise due to various combinations of a variety of different clinical problems, and that this alone is of limited value in understanding the etiology of the abnormalities, or in the treatment of them. It also suggests that the metabolic syndrome requires much more study before its designation as a 'syndrome' is truly warranted and before its clinical utility is adequately defined. In addition, the variable contribution of risk factors to the metabolic syndrome between countries 9 suggests that the definition of metabolic syndrome in different populations should be properly addressed, thereby to increase the comparability in different countries. CVD is the leading cause of death in many countries. 10 It has been demonstrated that CVD risk increases after menopause, which may be associated with the emergence of the features of metabolic syndrome from pre-to postmenopausal status. [11] [12] [13] [14] However, hormone replacement therapy for the menopausal women does not confer cardiovascular protection according to the Women's Health Initiative trial. 15 Therefore, estrogen deficiency may indirectly contribute to the increased risk of CVD in postmenopausal women.
The prevalence of obesity is increasing in many countries. 16, 17 In addition to increasing mortality, obesity has been known to be associated with higher risk of hypertension, diabetes, dyslipidemia and CVD. [18] [19] [20] [21] On the other hand, the main features of the syndrome cluster together more frequently than would be expected by chance alone, 1 and insulin resistance has been regarded as the basic defect leading to metabolic syndrome. [22] [23] [24] Taken together, these imply that a common mechanism, such as insulin resistance and/or obesity, underlies the metabolic syndrome. In this study, we investigated the prevalence of metabolic syndrome and its related factors, including age, menopausal status, BMI and insulin resistance index among non-diabetic, middleaged women.
Methods

Subjects and characterizations
Five hundred and ninety-four middle-aged women who attended the survey of CVD risk factors in a medical center in North Taiwan were recruited in 1998. The inclusion criteria were as follows: (1) aged from 40 to 64 years old; (2) denied any major disease which may influence their body weight (ex: diabetes mellitus, thyroid diseases etc.); (3) no current medication which may influence body weight (e.g.: hormone, glucocorticoid, antiobesity medications etc.). Menopause is defined as the absence of menstruation for 12 consecutive months, which is not due to surgical resection of uterus or ovaries. The anthropometric measurements, including height, weight, waist (WC) and hip circumferences (HC), and blood pressure measurement were performed as previously described. 21 Body mass index (BMI) was calculated as weight (kg) divided by height squared (m 2 ). This study has been approved by the Ethics Committee of National Taiwan University Hospital.
Laboratory tests
A venous blood sample was taken after 12 h of fasting for measuring plasma glucose, triglycerides, total cholesterol (TCHOL), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) as previously described. 21 The metabolic syndrome was defined clinically, based on the presence of three or more of the following National Cholesterol Education Panel (NCEP) criteria: 23 (1) central obesity (WC 490 cm in women), (2) a high triglyceride level (X1.69 mmol/l), (3) a low-HDL cholesterol level (o1.29 mmol/l in women), (4) high blood pressure (X130/85 mmHg), (5) a high fasting plasma glucose concentration (X6.1 mmol/l). Furthermore, the modified NCEP criteria using a lower WC cutoff with WC 480 cm in women was also applied for comparison due to a different definition of central obesity in this population. 6, 25 Plasma insulin levels were determined by a microparticle enzyme immunoassay using AxSYM system from Abbott Diagnostics (Abbott Laboratories, Dainabot Co. Ltd., Tokyo, Japan). The homeostasis model assessment is applied to estimate the degree of insulin resistance (HOMA-IR ¼ fasting insulin Â fasting plasma glucose/22.5, where insulin in mU/mL and glucose in mmol/l). 26 Informed consent was obtained from the subjects.
Statistical analyses
The data are presented as the means and s.d. unless indicated otherwise. BMI and HOMA-IR were grouped according to the calculated data in quartiles. Log transformation was used for variables with significant deviation from normal distribution, assessed by Kolmogorov-Smirnov test before further analyses. The frequency of metabolic syndrome and its components was calculated for participants according to menopausal status. The Wald w 2 test was used to evaluate the statistical significance and odds ratios of the prevalence rates of the metabolic syndrome. Several multivariate logistic regression models were performed with various combinations of age, menopausal status, BMI, and HOMA-IR groups as independent variables, and metabolic syndrome as the outcome variable. These statistical analyses were performed using the PC version of SPSS statistical software (10th version, SPSS Inc., Chicago, IL, USA).
Results
The basic characteristics of the subjects are shown in Table 1 according to menopausal status. The means of age, weight, BMI, WC, blood pressure, plasma TCHOL, HDL-C, LDL-C and triglycerides levels are higher in post-menopausal than in pre-menopausal women. However, statistically, the fasting plasma glucose, LDL-C, insulin levels, and HOMA-IR are not significantly different between the two groups. Moreover, the plasma TCHOL and LDL-C levels are not significantly different between women with and without metabolic syndrome either in pre-menopausal or post-menopausal women (data not shown).
The prevalence of metabolic syndrome and its individual components according to the menopausal status are shown in Table 2 . The prevalence of metabolic syndrome is 6.2% using the NCEP-ATP III criteria, and 8.9% using the modified Menopause and metabolic syndrome W-Y Lin et al NCEP-ATP III criteria. Post-menopausal women also have a significantly higher prevalence of central obesity, high blood pressure, and high triglycerides compared to pre-menopausal women.
The prevalence of metabolic syndrome using modified criteria, BMI, and HOMA-IR groups in quartiles (o0.93, 0.93-1.39, 1.40-2.13, X2.14 in HOMA-IR and o21.2, 21.2-22.7, 22.8-25.0, X25.1 kg/m 2 in BMI) is shown in Figure 1 .
We find that the prevalence of metabolic syndrome ranges from 1.4 to 23.0% in the quartiles of HOMA-IR groups. The prevalence of metabolic syndrome increases with the increments of HOMA-IR quartiles (test for trend, Po0.01). In addition, the prevalence of metabolic syndrome ranges from 0.7 to 22.3% in the quartiles of BMI groups. The prevalence of metabolic syndrome also increases with the increments of BMI quartiles (test for trend, Po0.01).
The odds ratios of having metabolic syndrome using multiple logistic regression analysis with age, menopausal 
Discussion
Post-menopausal women have been found to be at higher risk for metabolic syndrome than pre-menopausal women in Americans. 27 Similarly in our study, we also demonstrated that the prevalence of metabolic syndrome was higher in post-menopausal than pre-menopausal women (9.4 versus 4.2% using the NCEP criteria, and 13.7 versus 5.8% using the modified NCEP criteria). Furthermore, we found that both BMI and insulin resistance index were independently associated with the prevalence of metabolic syndrome in non-diabetic, aged 40-64 years women. However, with adjustment for age, BMI, insulin resistance, there was an increased odds ratio of having metabolic syndrome without statistically significant difference in post-menopausal women. It could be due to the small sample size or multicolinearity in these variables in our study. The transition from pre-to post-menopause may be associated with features of the metabolic syndrome, including an increased central body fat, a shift toward a more atherogenic lipid profile, and high blood pressure. 12, [28] [29] [30] The emergence of these CVD risk factors may be a direct result of ovarian failure, or an indirect result of the metabolic consequences of body fat centralization with estrogen deficiency. Previous studies have also demonstrated that menopause is associated with a modest increase in total fatness and an accelerated accumulation of central body fat that exceeds changes normally attributed to the aging process. 28 Similarly in our studies, post-menopausal women, when compared to pre-menopausal women, had a higher WC, plasma triglycerides level and blood pressure (Table 1 ). In addition, most studies have shown that plasma HDL-C levels either fall slightly 12, 13, 31 or remain stable 11 with menopause. However, plasma HDL-C levels have been found to increase with menopause in Koreans and Iranians. 29, 32 In our study, plasma HDL-C level increased with menopause and the prevalence of low HDL-C decreased with menopause (Tables 1 and 2 ). The literature to date is not clear as to whether menopause itself is directly associated with increased insulin resistance. Lindheim et al., 33 for example, have found reduced insulin sensitivity (i.e. higher insulin resistance) in post-menopausal women, compared with BMI-matched pre-menopausal women. However, others have shown no significant difference in insulin sensitivity among post-menopausal women compared to pre-menopausal women. 34, 35 In our study, there was no significant difference in fasting plasma glucose, insulin levels, HOMA-IR, and prevalence of hyperglycemia between pre-menopausal and post-menopausal women (Tables 1 and 2 ). It has been recognized that the underlying pathophysiology of metabolic syndrome is related to hyperinsulinemia and insulin resistance. 1, [22] [23] [24] 36 However, other studies have shown that obesity is the central feature of metabolic syndrome. 37, 38 In our study, both BMI and insulin resistance index were independently associated with the prevalence of metabolic syndrome in non-diabetic middle-aged women, adjusted for age and menopausal status (Table 3) . Therefore, our results implicated that insulin resistance and obesity Menopause and metabolic syndrome W-Y Lin et al were related to the development of metabolic syndrome. However, when putting BMI and HOMA-IR together into model 5 in Table 3 , we found that only HOMA-IR was associated with the prevalence of metabolic syndrome with statistically significant difference although the prevalence of metabolic syndrome increased with an increment of BMI without statistical significance. It could be due to the small sample size or multicolinearity between BMI and HOMA-IR in our study. Although CVD risk increases with metabolic syndrome in western countries, 1,2 it remains unclear whether metabolic syndrome can predict CVD independently in Asians from the limited evidences of prospective studies. In a 7-year study among the middle-aged Japanese, for examples, clustered features of the metabolic syndrome are closely associated with development of CVD. 39 In contrast, metabolic syndrome does not predict CVD independently of other established CVD risk factors in the non-diabetic American Indians. 40 Recently, the NCEP-defined metabolic syndrome predicts the 8-year CVD risk in Japanese men with type 2 diabetes, but not in women with type 2 diabetes. 41 It is possible that the (modified) NCEP definition identifies a heterogeneous group of individuals with the metabolic syndrome in different populations. 9 Therefore, ethnicspecific definitions of metabolic syndrome are warranted in an attempt to adapt for global use.
In conclusion, we have demonstrated that the prevalence of metabolic syndrome was higher in post-menopausal than pre-menopausal women, using either the NCEP or modified NCEP criteria. BMI and insulin resistance were positively associated with the odds ratios of having metabolic syndrome in the non-diabetic, middle-aged Taiwanese women. However, our study was limited by the cross-sectional design and potentially biased from the subjects. Further research may be required as to whether the transition to menopause increases CVD risk in all women or only those who develop features of the metabolic syndrome. Furthermore, a better understanding of these metabolic changes with menopause may aid in the recognition and treatment of women at risk for CVD.
